Drug Profile


Alternative Names: C 105; L-alpha-methylphenethylamine; L-amfetamine; L-amfetamine sulfate; L-amphetamine; L-amphetamine sulfate; Levamfetamine; Levoamphetamine

Latest Information Update: 26 Sep 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Brown University; Sention
  • Developer Cognition Pharmaceuticals
  • Class Amphetamines; Antidementias; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants; Neurotransmitter modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cognition disorders

Most Recent Events

  • 19 Dec 2008 Interim efficacy and safety data from the phase II, NCT00529581 trial in patients with cognitive impairment due to multiple sclerosis (Cognition disorders) released by Cognition Pharmaceuticals
  • 30 Apr 2008 Cognition Pharmaceuticals completes the phase II, NCT00529581 trial for cognitive impairment in patients with multiple sclerosis (Cognitive disorders) in USA
  • 19 Jan 2005 Sention completes phase I trials in Cognitive disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top